NASDAQ$MNKD
MannKind Corp · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
MannKind reported a ninth consecutive quarter of revenue growth, driven by increased sales of Tyvaso DPI and Afrezza and advanced two orphan lung programs to human studies.
MannKind Corporation reported total revenues of $72 million for Q2 2024, a 49% increase compared to Q2 2023. The company is approaching an annual revenue run rate of over $275 million based on the first half of 2024.
- Total revenues reached $72 million, a 49% increase compared to Q2 2023.
- Royalties from collaboration increased by 34% due to increased sales of Tyvaso DPI.
- Revenue from collaborations and services increased by 132% primarily due to increased manufacturing activities for Tyvaso DPI.
- Afrezza net revenue increased by 20% due to price adjustments and higher demand.
Headline financials
Revenue & EPS history
MannKind · Revenue · Quarterly
$72M
Revenue by segment
MannKind · $31M total across 3 segments · Q3 2023
- Afrezza$13.5M—43.4%
- Collaborations and services$13.1M—42.2%
- V-Go$4.45M—14.3%
Forward guidance
MannKind is focused on advancing its pipeline, driving in-line growth, and reducing debt to deliver sustainable value.
Tailwinds
- Advancing orphan lung programs to human studies (Phase 1 and Phase 3).
- MNKD-101 Phase 3 clinical trial activities initiated.
- MNKD-201 Phase 1 clinical trial on schedule to read out 4Q 2024.
- Afrezza INHALE-1 pediatric phase 3 clinical trial primary endpoint analysis expected in 4Q 2024.
- Full results from Afrezza INHALE-1 pediatric phase 3 clinical trial expected in 1H 2025.
Headwinds
- Risks associated with manufacturing and supply.
- Risks associated with developing product candidates.
- Risks and uncertainties related to unforeseen delays that may impact the timing of progressing clinical trials and reporting data.
- Risks associated with safety and other complications of our products and product candidates.
- Risks associated with the regulatory review process.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.4%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+1.5%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+44.9%
Q3 2016
Best reaction
-28.5%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.5% | +17.5% | +18.5% | |
| Q4 2025 | -6.9% | -16.3% | -34.9% | |
| Q3 2025 | +10.6% | -1.1% | +3.6% | |
| Q1 2025 | -4.5% | -2.7% | -9.7% | |
| Q4 2024 | -4.4% | -5.9% | -8.0% | |
| Q3 2024 | -1.2% | -4.8% | -8.6% | |
| Q2 2024 | -1.5% | -1.5% | +12.5% | |
| Q1 2024 | -3.6% | -1.3% | +4.5% | |
| Q4 2023 | +9.5% | +25.7% | +26.5% | |
| Q3 2023 | -0.8% | -6.8% | -0.3% | |
| Q2 2023 | +15.5% | +11.2% | -3.8% | |
| Q1 2023 | +13.4% | +9.0% | +6.2% | |
| Q4 2022 | +4.2% | +1.7% | -23.1% | |
| Q3 2022 | +6.3% | +20.7% | +32.8% | |
| Q2 2022 | -1.4% | -4.6% | -9.0% | |
| Q1 2022 | -8.7% | -8.7% | +42.7% | |
| Q4 2021 | -25.7% | -24.9% | -5.2% | |
| Q3 2021 | -0.6% | +3.1% | -14.3% | |
| Q2 2021 | +5.1% | +5.4% | +20.8% | |
| Q1 2021 | -8.4% | -3.9% | -8.0% | |
| Q4 2020 | -4.5% | -36.8% | -40.0% | |
| Q3 2020 | +8.8% | +19.0% | +43.9% | |
| Q2 2020 | +0.0% | -4.2% | -1.2% | |
| Q1 2020 | -2.2% | -0.7% | +4.5% | |
| Q4 2019 | -7.9% | -16.4% | -27.6% | |
| Q3 2019 | -15.1% | -16.8% | -18.8% | |
| Q2 2019 | -0.9% | +4.6% | +13.9% | |
| Q1 2019 | -12.3% | -19.4% | -25.2% | |
| Q4 2018 | +23.8% | +17.2% | +27.8% | |
| Q3 2018 | +0.0% | -1.1% | -2.7% | |
| Q2 2018 | -26.8% | -29.3% | -29.9% | |
| Q1 2018 | +2.3% | +8.7% | +13.3% | |
| Q4 2017 | -10.4% | -13.5% | -30.3% | |
| Q3 2017 | -7.1% | +0.3% | -4.3% | |
| Q2 2017 | -5.7% | -2.5% | +61.5% | |
| Q1 2017 | +13.8% | -5.4% | +39.3% | |
| Q4 2016 | +9.9% | +2.5% | -34.2% | |
| Q3 2016 | +44.9% | +51.2% | +51.2% | |
| Q2 2016 | -6.2% | +2.0% | -27.6% | |
| Q1 2016 | -28.5% | — | — | |
| Q4 2015 | +6.0% | — | — | |
| Q3 2015 | -19.9% | — | — | |
| Q2 2015 | +4.5% | — | — | |
| Q1 2015 | -8.4% | — | — | |
| Q4 2014 | +2.8% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -8.0% | — | — | |
| Q1 2014 | +5.8% | — | — | |
| Q4 2013 | +5.9% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q2 2013 | -5.1% | — | — | |
| Q1 2013 | +11.0% | — | — | |
| Q4 2012 | -1.9% | — | — | |
| Q3 2012 | +2.6% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | -8.3% | — | — | |
| Q4 2011 | +7.9% | — | — | |
| Q3 2011 | -1.6% | — | — | |
| Q2 2011 | -10.1% | — | — | |
| Q1 2011 | -11.8% | — | — | |
| Q4 2010 | -5.5% | — | — | |
| Q3 2010 | -2.3% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +3.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro